by Lori Solomon The U.S. Food and Drug Administration approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages 6 to 17 years with functional constipation. The approval was based on data from 328 participants who were randomly assigned (1:1) to receive Linzess or placebo. A statistically significant benefit and clinically meaningful improvement was seen for...
